Pfizer and Cartography Biosciences struck a multiyear collaboration giving Pfizer options to license tumor‑selective antigens discovered with Cartography’s Atlas and Summit platforms. Pfizer agreed to up to $65 million in near‑term payments and a deal value that could reach roughly $865 million with milestones, plus royalties. Cartography will use its single‑cell and cell‑state profiling datasets to nominate antigen targets; Pfizer can opt into programs and assume development and commercialization for selected assets. The deal reflects Big Pharma demand for precision antigen discovery tools aimed at improving safety and selectivity for T‑cell therapies and engager modalities.